• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Biomea Fusion Inc.

    8/13/25 4:30:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMEA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Biomea Fusion, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    09077A106

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09077A106


    1Names of Reporting Persons

    Rainer M. Erdtmann
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,494,434.00
    6Shared Voting Power

    480,790.00
    7Sole Dispositive Power

    2,494,434.00
    8Shared Dispositive Power

    480,790.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,975,224.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    09077A106


    1Names of Reporting Persons

    Point Sur Investors, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    480,790.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    480,790.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    480,790.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    09077A106


    1Names of Reporting Persons

    Point Sur Investors Fund I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    228,470.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    228,470.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    228,470.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Biomea Fusion, Inc.
    (b)Address of issuer's principal executive offices:

    1599 Industrial Road, San Carlos, CA 94070
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities listed below, who are collectively referred to herein as "Reporting Persons," with respect to the shares of common stock of Biomea Fusion, Inc. (the "Company"), par value $0.0001 per share (the "Shares"). (i) Rainer M. Erdtmann, a citizen of the United States of America; (ii) Point Sur Investors, LLC, a Delaware limited liability company ("Point Sur LLC") ; and (iii) Point Sur Investors Fund I, L.P., a Delaware limited partnership ("Point Sur Investors Fund").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Rainer M. Erdtmann is c/o Biomea Fusion, Inc., 1599 Industrial Road, San Carlos, CA 94070. The address of the principal business office of Point Sur LLC and Point Sur Investors Fund is 1073 Arlington Blvd., El Cerrito, CA 94530.
    (c)Citizenship:

    See Item 2(a) above.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    09077A106
    Item 4.Ownership
    (a)Amount beneficially owned:

    Rainer M. Erdtmann may be deemed to beneficially own 2,494,434 Shares, consisting of: (i) 482,404 Shares issuable upon the exercise of stock options exercisable within 60 days held directly by Rainer M. Erdtmann, (ii) 643,027 shares held directly by Rainer M. Erdtmann, (iii) an aggregate of 59,400 Shares held by the children of Rainer M. Erdtmann, (iv) 174,614 Shares held by a trust with an independent trustee ("Trust 1"); and (v) 1,134,989 Shares held by a separate trust with an independent trustee ("Trust 2"). Point Sur Investors Fund directly holds 228,470 Shares. Point Sur LLC directly holds 252,320 Shares. Point Sur LLC is the General Partner of Point Sur Investors Fund. Rainer M. Erdtmann is a managing member of Point Sur LLC and, as such, Mr. Erdtmann has shared voting and dispositive power over the Shares held by both Point Sur Investors Fund and Point Sur LLC.
    (b)Percent of class:

    The percent of class of the outstanding Shares beneficially owned by the Reporting Persons in Item 4(a) are based on (i) 57,022,250 Shares outstanding as of the completion of the offering of the Shares referred to in the Company's Prospectus Supplement (to the Prospectus dated October 24, 2022, Registration No. 333-267884), filed on June 18, 2025 and (ii) 482,404 Shares issuable within 60 days after June 30, 2025 upon the exercise of options held directly by Rainer M. Erdtmann, which have been added to the Shares reported as outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by this Item 4(c)(ii) is set forth in Row 6 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rainer M. Erdtmann
     
    Signature:/s/ Rainer M. Erdtmann
    Name/Title:Rainer M. Erdtmann
    Date:08/13/2025
     
    Point Sur Investors, LLC
     
    Signature:/s/ Rainer M. Erdtmann
    Name/Title:Rainer M. Erdtmann, Authorized Signatory
    Date:08/13/2025
     
    Point Sur Investors Fund I, L.P.
     
    Signature:/s/ Rainer M. Erdtmann
    Name/Title:Rainer M. Erdtmann, Authorized Signatory
    Date:08/13/2025
    Get the next $BMEA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMEA

    DatePrice TargetRatingAnalyst
    6/3/2025$7.00Overweight
    Piper Sandler
    10/9/2024$128.00Buy
    Edward Jones
    9/27/2024$18.00Neutral → Buy
    Rodman & Renshaw
    9/27/2024$54.00Hold → Buy
    Truist
    8/29/2024$25.00Overweight
    CapitalOne
    6/11/2024Buy → Hold
    Truist
    6/7/2024$30.00 → $5.00Overweight → Equal Weight
    Barclays
    4/2/2024$51.00 → $14.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Interim CEO Hitchcock Michael J.M.

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    8/13/25 4:15:10 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M gifted 70,000 shares and received a gift of 30,000 shares, decreasing direct ownership by 10% to 643,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    8/13/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Former Director Chen Bihua

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    8/1/25 4:05:40 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    10/1/24 4:30:12 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Valle Franco was granted 4,448 shares and bought $55,361 worth of shares (12,509 units at $4.43), increasing direct ownership by 66% to 42,500 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    6/12/24 4:30:07 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    SEC Filings

    View All

    SEC Form EFFECT filed by Biomea Fusion Inc.

    EFFECT - Biomea Fusion, Inc. (0001840439) (Filer)

    8/18/25 12:15:16 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biomea Fusion Inc.

    SCHEDULE 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

    8/13/25 4:30:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Biomea Fusion Inc.

    S-3 - Biomea Fusion, Inc. (0001840439) (Filer)

    8/5/25 4:41:42 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

    Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and improved beta-cell function subsequent to the dosing period In a rodent model of T2D, icovamenib in combination with low-dose semaglutide, promoted enhanced glycemic control and weight loss with complete lean mass preservation Icovamenib promoted healthy myotube morphology and reduced drug-induced atrophy in ex-vivo human myotube cultures Next-generation oral GLP-1 receptor agonist (RA) candidate, BMF-650, demonstrated robust, dose-de

    8/5/25 4:05:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Appoints Julianne Averill to its Board of Directors

    SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the "Board"), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. "Julianne is an accomplished leader whose extensive financial, operational, and strategic expertise in the life sciences and digital health industries will be a tremendous asset to Biomea. Her prov

    7/24/25 7:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

    In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide aloneIcovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube culturesIn severely insulin-deficient patients from the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, three weeks after last dose SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (NASDAQ:

    6/23/25 7:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Biomea Fusion with a new price target

    Piper Sandler resumed coverage of Biomea Fusion with a rating of Overweight and set a new price target of $7.00

    6/3/25 7:31:50 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edward Jones initiated coverage on Biomea Fusion with a new price target

    Edward Jones initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $128.00

    10/9/24 8:20:08 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion upgraded by Rodman & Renshaw with a new price target

    Rodman & Renshaw upgraded Biomea Fusion from Neutral to Buy and set a new price target of $18.00

    9/27/24 7:30:48 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Financials

    Live finance-specific insights

    View All

    Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

    Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company

    12/17/24 8:10:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

    REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes. Conference Call and Webcast Details Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to reg

    12/16/24 6:15:01 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

    Preliminary data supports BMF-500's potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability profile, with no dose-limiting toxicities observed across all dose levelsPharmacokinetic and pharmacodynamic data confirmed on-target FMS-like tyrosine kinase 3 (FLT3) inhibition, demonstrating dose-proportional activity and good compartmental penetrationPreliminary Phase I data for BMF-500 in R/R acute leukemia patients with FLT3 gene mutations having failed gilteritinib indicated clinical activity with evidence of responses, including a first complete response with incomplete hematologic recove

    12/9/24 4:01:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Leadership Updates

    Live Leadership Updates

    View All

    Biomea Fusion Appoints Julianne Averill to its Board of Directors

    SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the "Board"), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service. "Julianne is an accomplished leader whose extensive financial, operational, and strategic expertise in the life sciences and digital health industries will be a tremendous asset to Biomea. Her prov

    7/24/25 7:00:00 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

    Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapyBiomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closed REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 202

    5/5/25 4:05:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

    Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, reported

    3/31/25 4:10:00 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

    SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

    11/12/24 12:31:45 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

    SC 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

    7/10/24 6:39:58 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Biomea Fusion Inc.

    SC 13G - Biomea Fusion, Inc. (0001840439) (Subject)

    4/10/24 9:45:50 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care